Altimmune ALT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.7%+7.8pp | -50.6%+2.0pp | -52.6%+3.3pp | -55.9%+1.4pp | -57.3%+2.6pp | |
| Return on assets | -37%+5.1pp | -42%+3.8pp | -45.8%+2.4pp | -48.3%+4.0pp | -52.2%+2.1pp | |
| Liquidity | ||||||
| Current ratio | 29.6×+11.0× | 18.5×+1.4× | 17.2×-3.3× | 20.4×+4.6× | 15.8×+2.7× | |
| Quick ratio | 29.6×+11.0× | 18.5×+1.4× | 17.2×-3.3× | 20.4×+4.6× | 15.8×+2.7× | |
| Cash ratio | 8.6×+5.7× | 2.9×-1.9× | 4.9×-15.0× | 19.9×+14.8× | 5×+1.5× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.2×+0.1× | 0.1×0.0× | 0.1×+0.1× | 0×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×+0.1× | 0.1×0.0× | 0.1×+0.1× | 0×0.0× | |
| Interest coverage | -35.9×+21.9× | -57.8×+61.1× | -118.9×+228× | -346.9×+10,563× | -10,910.3×+553× | |
| Per Share | ||||||
| Book value per share | $2.28-10.6% | $2.55+23.0% | $2.08+4.8% | $1.98+5.2% | $1.88+8.2% | |
| Valuation | ||||||
| Market capitalization | $558.14M-2.1% | $376.68M+13.2% | $332.73M-42.9% | $583.16M+51.4% | $385.07M-24.9% | |
| Enterprise value | $495.27M-5.0% | $368.56M+28.8% | $286.14M-31.0% | $414.58M+23.3% | $336.17M-29.6% | |
| Price / book | 2×-2.0× | 1.7×-0.1× | 1.8×-1.8× | 3.6×+0.9× | 2.7×-1.4× | |
| Earnings yield | -16.3%-0.5pp | -23.4%+1.8pp | -25.2%-10.2pp | -15%+8.4pp | -23.4%-4.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Altimmune's ratios come from?
- Every ratio is computed from Altimmune's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
